Companies in pre-clinical contractual research

Montreal Metro can pride itself for having some of the world leaders in the non-clinical contractual research established on its territory.

 

Some of the key players include:

 

Charles River Laboratories Preclinical Services (formerly CTBR)

www.criver.com/preclinical_services

President Global Preclinical Services: Nancy A. Gillett

1,500 employees

 

As one of the largest preclinical services company, Charles River Preclinical Services offers a highly technical and broad range of preclinical services in its Montreal facility. Services offered to the industry include discovery, toxicology, pathology, drug metabolism, pharmacokinetics and laboratory sciences.

 

CRL Preclinical Services in Montreal is the largest single preclinical facility in the world. It employs over 1,500 people and it can run all types of studies required by regulatory agencies such as the US FDA for the filing of a new drug.

 

AccelLAB Inc.

www.accellab.com/index.html

CEO : Guy Leclerc, M.D.

VP Science: Louis-George Guy, Ph.D.

40 employees

 

AccelLAB is a non-clinical Contract Research Organization focused on large animal testing with a special focus in the field of interventional cardiology and regenerative medicine offering services from early drug or device development to late-stage non-clinical GLP studies.

 

AccelLAB offers its clients services in coronary stent development, drug-eluting stent studies, peripheral device development, cardiac cell transplant studies, etc.

 

Its team has been working together for over 5 years and is made of specialists such as veterinarians, animal health technicians, pathologists, and histology experts. This team is driven by Dr. Guy Leclerc, a lead interventional cardiologist from the University of Montreal Hospital.

 

 

Companies in clinical contractual research

 

Montreal Metro has attracted some of the major CROs from the USA and Europe. These companies have operations in the region and have elected Montreal as the head for their Canadian operations.

 

Montreal has also been a very fertile soil for the creation of important local CROs with an international reputation.

 

 

Quintiles Canada Inc.

www.quintiles.com

Director Global Sales: Martine Courtemanche

100 employees

 

Quintiles Transnational Corp., the world leader in CROs, has chosen Montreal as the head of its Canadian operations. With more than 100 employees, Quintiles Canada conducts clinical studies from phases II to phase IV and phase I/II studies in oncology. It offers a full range of services to pharmaceutical and biotech customers from Canada but also from the USA and abroad.

 

Quintiles Canada enjoys an excellent reputation in clinical studies and is pleased to benefit from an excellent network of clinicians and an easier access to patients in Canada and in Montreal in particular.

 

Algorithme Pharma Inc.

www.algopharm.com

CEO : Louis Caillé

lcaille@algopharm.com

400 employees

 

Algorithme Pharma, another Canadian CRO, was founded 25 years ago in Montreal. It is a winner of the Canada’s 50 Best Managed Companies award.

 

Algorithme Pharma is a specialist of phase I and bioequivalence studies. It also runs a bioanalytical laboratory staffed with more than 90 people. Its clinical facilities include over 270 beds for phase I and bioequivalence studies. Algorithme Pharma prides itself of its unique access to a bank of volunteers of more than 52,000 potential study participants that includes special population segments and specific patient populations.

 

The company has been successfully audited by the North American, European and Brazilian regulatory authorities.

 

Cato Research Canada Inc.

www.cato.com

Regional Director: Michelle Frenette

60 employees

 

Established in Montreal in 1992, Cato Research Canada comprises 60 employees including a group of scientists who assist sponsors at all steps of the drug development process, and a team of experienced regional clinical research associates located in major Canadian cities.

 

Cato Research Canada offers a wide range of pharmaceutical development services, including nonclinical development strategy and toxicology study design, conduct and management; regulatory strategy, interactions with regulatory authorities and preparation of submissions; design, conduct and management of clinical studies (Phases I to IV); pharmacovigilance and medical monitoring; technical and medical writing; data management, statistical analysis and preparation of clinical study reports.

 

JSS Medical Research Inc.

www.jssresearch.com/home/

President: John S. Sampalis

45 employees

 

JSS Medical Research is a full scope integrated CRO that conducts phase II to IV clinical studies with proven expertise in post-marketing projects. The company was created in 1992 by Dr John S. Sampalis who is recognized as one of Canada's leading clinical epidemiologists, as well as the top trauma researcher in the country.

 

In a market where phase IV studies are now required to ascertain the true effectiveness and safety of a drug, the expertise of JSS Medical Research in clinical epidemiology and its scientific rigor have successfully helped its clients to address specific issues related to their marketed drugs. JSS Medical Research assists them from clinical study conception, protocol design to result dissemination in preparation of abstracts, conference material and peer reviewed published manuscript.

 

This document had been prepared by: Montréal International